Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Scleroderma Archive
2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2018 - 2017 - 2016 - 2015

February 2016 Scleroderma News

Potential Scleroderma Gene Therapy Moving into Preclinical Dosing Study, Fibrocell Reports. Fibrocell has finished a proof-of-concept trial on FCX-013 for the treatment of linear scleroderma. The trial examined the efficacy of FCX-013 in reducing dermal thickness in fibrotic tissue. Scleroderma News Today, 02/09/2016. (Also see: Linear Scleroderma Treatments)

FDA Clears Uptravi (Selexipag) for Pulmonary Arterial Hypertension. Uptravi (Selexipag) was shown to be effective in reducing hospitalization for PAH and reducing the risks of disease progression compared to placebo. FDA, 12/22/2015. (Also see Treatments for Pulmonary Hypertension)

OFEV (nintedanib) to Be Tested in Systemic Sclerosis Patients (SSc) with Interstitial Lung Disease (ILD). The potential use of nintedanib in conditions that commonly occur with fibrotic lung conditions, such as systemic sclerosis are being investigated. Scleroderma News, 12/22/2015. (Also see Pulmonary Fibrosis Treatments and Clinical Trials)

Anti–IFI16 antibodies in scleroderma are associated with digital gangrene. Anti–IFI16 antibodies are associated with digital gangrene in scleroderma. PubMed, Arthritis Rheumatol, 12/29/2015. (Also see Gangrene)

Symptomatic and electrodiagnostic features of peripheral neuropathy in scleroderma. While symptoms or objective evidence of peripheral neuropathy are common among patients with scleroderma, the cause may often be attributed to co-morbid non-scleroderma related conditions. PubMed, Arthritis Care Res (Hoboken), 12/14/2015. (Also see Musculoskeletal Involvement)

Strategy for treatment of fibrosis in systemic sclerosis: Present and future. This review describes recent advances in the strategy for treatment of fibrosis in SSc and future perspectives. Wiley Online Library, 01/04/2016. (Also see Scleroderma Clinical Trials)

Biomarkers in systemic sclerosis (SSc): Their potential to predict clinical courses. Biomarkers that can predict clinical features, disease progress, therapeutic response and prognosis are heterogeneous among patients with systemic sclerosis. Wiley Online Library, 01/04/2016. (Also see Prognosis and Mortality)

B lymphocytes in systemic sclerosis (SSc): Abnormalities and therapeutic targets. Altered B–cell function may result in tissue fibrosis, as well as autoimmunity and although further studies and greater understanding are needed, B cells are potential therapeutic targets in SSc. Wiley Online Library, 01/04/2016. (Also see B Cells and T Cells)

Association of elevated α–defensin levels with interstitial pneumonia in patients with systemic sclerosis (SSc–ILD). Bronchoalveolar lavage fluid levels of defensins and IL-8 were higher in SSc–ILD than in healthy controls, and are associated with various clinical disease parameters. PubMed, Respir Res, 2015 Dec 10;16:148. (Also see Interleukins)

The IL-33 gene is related to increased susceptibility to systemic sclerosis (SSc). The aim of the present study was to detect the potential association of IL-33 gene polymorphisms on the susceptibility of SSc. Springer Link 01/07/2016. (Also see Interleukins)

Sublingual Abnormalities in Systemic Sclerosis (SSc). This feasibility study confirms the presence of clinical sublingual abnormalities in SSc and the functional significance and pathogenesis of this abnormality warrant further study. PubMed, J Clin Rheumatol, 2016 Jan;22(1):19-21. (Also see Dental Involvement)

Go to Scleroderma Medical News: January 2016

Giving Assistant
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Pam Hop, Margaret Roof, Winifred Schillberg, Arnold Slotkin, and Juliet Youkhana. Plus donations in honor of Kim Thwaits, and in loving memory of Marta Marx, Jim Miller, and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE button.


TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!

SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content. Privacy Policy.

The most important thing in the world to know about scleroderma is!

Donate Now
Copyright 1998-2018, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.